The Weekly Roundup: October 8-13

Jeffrey Cizenski, MD, FAAD: Eczema Representation Through Under My Skin Documentary

In this expert Q&A, dermatologist Jeffrey Cizenski, MD, FAAD, offers perspectives on National Eczema Awareness Month and AbbVie's Under My Skin documentary.

Hair Today, Gone Tomorrow: Consulting Patients on Preventing Hair Breakage

Dermatology Times Editor in Chief Zoe Diana Draelos, MD, delves into the topic of hair health, including pearls and best practices for preventing hair breakage in patients.

JNJ-2113 Advances in Clinical Development Programs for Plaque Psoriasis, Ulcerative Colitis

Protagonist Therapeutics has just announced the company's eligibility to receive $60 million of milestone payments for JNJ-2113 to enter into clinical development programs led by Janssen.

AnaptysBio Releases Positive Top-Line Phase 3 Results of Imsidolimab for GPP Flares

A BLA is expected to be submitted by Q3 of 2024.

POLL: How Often Do You Collaborate With Gynecologists Regarding Genital Skin Cancers?

Click here to answer this week's skin cancer poll.

Higher Treatment, Health Care Costs Associated With Advanced Melanomas

Greater treatment costs are associated with more advanced stages of melanoma, particularly due to increasing prices of treatments.

From Awareness to Action: Enhancing Patient Care

The October issue of Dermatology Times spotlights numerous awareness campaigns and their impact on improving and enhancing patient care.

National Eczema Association Receives Grant from CDC for AD Project

The grant will go toward supporting the group's project, "Atopic Dermatitis is More Than a Skin Disease: Raising Awareness and Improving Care."

Supporting the Mental Health Needs of Dermatology Patients

This World Mental Health Day, Dermatology Times is reviewing the important and often comorbid mental health concerns linked to common dermatologic conditions.

Advances in Diagnosing and Treating Atopic Dermatitis in the Elderly

AD in the elderly demands specialized attention, considering the unique challenges presented by concurrent skin conditions and underlying systemic diseases.

Pointers With Portela: Tackling Blackheads and Whiteheads

In this week’s Pointers With Portela, the 208SkinDoc reviews his tips for treating blackheads and whiteheads, as well as recommended products.

Reduced Mortality Associated With Vitiligo

In a population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about the risks of mortality among these patients.

Dermatologists on Fire: Stasis vs Change

This World Mental Health Day, Zoe Diana Draelos, MD, discusses the importance of prioritizing physician well-being in order to prevent burnout, or as Draelos instead refers to it, "stasis."

Finding Balance in a Busy Conference Season

Kristina Collins, MD, delves into the importance of being present in the moments you have control over and making self-care a priority on the road.

Journal Digest: October 10

This week’s collection of the latest dermatologic studies covers the incidence of keratinocyte carcinomas, upadacitinib used to treat discoid lupus erythematosus, considerations about hair camouflage for Black women with alopecia, and parent perspectives of infants undergoing surgical treatment for congenital melanocytic nevus.

Gut Microbiome Has Significant Impact on Atopic Dermatitis

The impact begins in utero, with the diet and health of the mother playing a key role in the potential for a child to develop diseases.

The Many Considerations of Managing Generalized Pustular Psoriasis

Experts discuss the treatment landscape of generalized pustular psoriasis as well as review difficult cases of GPP.

New Phase 3 Data on Long-Term Efficacy of Upadacitinib in Atopic Dermatitis Presented at EADV

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

FDA Clears IND for KYV-101 for the Treatment of Scleroderma

Kyverna Therapeutics can now initiate its phase 1/2 open-label, multicenter study of KYV-101.

Viewing Atopic Dermatitis and Its Impact From a Patient Perspective

Dermatologist Diego Ruiz Dasilva, MD, FAAD, and a patient with atopic dermatitis discuss the patient journey from initial symptoms to diagnosis to treatment selection.

Sexual and Gender Minority Patients With Chronic Inflammatory Skin Diseases Affected by Obstacles to Care

Sexual and gender minority patients with chronic inflammatory skin diseases may be disproportionately influenced by cost and noncost obstacles to health care.

Study Explores Dermatologic Patient Journey to Enhance Patient Care and Address Unmet Needs

A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.

Bristol Myers Squibb Presents 3-Year Safety and Efficacy Data of Deucravacitinib for PsO at EADV

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Incyte Announces Positive 52-Week Data at EADV of Povorcitinib for Extensive Nonsegmental Vitiligo

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.

Eric Simpson, MD, Discusses Recently Announced EADV Data On Tapinarof Cream for AD Down to 2 Years

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Acne Conglobata: An Overview and Effective Management Strategies

The impact of acne conglobata on individuals underscores the crucial role dermatologists play in providing effective diagnosis, treatment, and emotional support.

Interim Data From Almirall's POSITIVE Study Reveals Significant Well-Being Improvements Among Psoriasis Patients

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3

AbbVie announced the 24- and 52-week data at EADV 2023.

October Pipeline Preview

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

Living With Pachyonychia Congenita: Patient Perspectives and Activism

The PC Project provides patients with access to the International PC Research Registry for clinical help with their rare and painful skin condition.

Sue Ellen Cox, MD, Looks Ahead to Hyperhidrosis Awareness Month

November is Hyperhidrosis Awareness Month, and dermatology clinicians are gearing up for another month of raising awareness to improve patient outcomes.

Artificial Intelligence: Friend or Foe?

This month's cover feature delves into the new applications and use of AI in dermatology and considers how AI can support clinicians rather than hinder them.

Arcutis Presents Positive Roflumilast Foam Data From ARRECTOR Trial in Scalp and Body PsO at EADV

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

Psychodermatology: Exploring the Connections Between Dermatology and Psychiatry in Dermatillomania

Last week was Body-Focused Repetitive Behaviors Awareness Week. Related to dermatology, dermatillomania, also known as skin picking disorder, is a condition that requires empathy and understanding year round.

ADvantage, ADvocate Studies Support Clinical Improvements of AD With Lebrikizumab

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

Amlitelimab Significantly Improves Average EASI Scores in Phase 2b AD Study

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

Bimekizumab Achieved Meaningful Clinical Improvements in Hidradenitis Suppurativa, According to Data From EADV

UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.

Trevi Therapeutics Announces New Phase 2b/3 Results of Haduvio for Prurigo Nodularis

The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.

Treatment-Related Acne After Ruxolitinib Application for Vitiligo Occurred in Patients Without History of Acne